author = "Lorite, Juan"
1

Encontrado 8 documentos, página mostrada 1 de 1

Thymus × pseudogranatensis (Labiatae), a new hybrid from Sierra Nevada (Spain) Thymus × pseudogranatensis (Labiatae), nuevo híbrido para Sierra Nevada (España)

Description: Thymus × pseudogranatensis Vizoso, F.B. Navarro & Lorite, a new spontaneous hybrid of Th. granatensis Boiss. subsp. granatensis and Th. zygis L. subsp. gracilis (Boiss.) R. Morales, collected in the dolomitic areas of Sierra Nevada (SE Spain), is described. Morphological characters of the new nothos...
Language(s): Inglés

Nutraceutical composition, antioxidant activity and hypocholesterolemic effect of a water-soluble enzymatic extract from rice bran

Description: This study was designed to characterize the nutraceutical composition of a water-soluble enzymatic extract from rice bran (EERB) and to evaluate its antioxidant and hypocholesterolemic activities. The EERB contains broad functional components in water soluble form such as sterols, tocopherols, tocot...
Language(s): Inglés

Recovery of MERRF Fibroblasts and Cybrids Pathophysiology by Coenzyme Q 10

Description: Mitochondrial DNA mutations are an important cause of human disease for which there is no effective treatment. Myoclonic epilepsy with ragged-red fibers (MERRF) is a mitochondrial disease usually caused by point mutations in transfer RNA genes encoded by mitochondrial DNA. The most common mutation a...
Language(s): Inglés

Secondary coenzyme Q10 deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts

Description: 9 páginas. , Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is a mitochondrial disease most usually caused by point mutations in tRNA genes encoded by mtDNA. Here, we report on how this mutation affects mitochondrial function in primary fibroblast cultures establishe...
Language(s): Inglés

Guía clínica de la enfermedad de Pompe de inicio tardío Clinical guidelines for late-onset Pompe disease

Description: English version available at www.neurologia.com , Hasta 2006, la enfermedad de Pompe o glucogenosis tipo II era una enfermedad incurable y con tratamiento meramente paliativo. El desarrollo de la terapia de sustitución con la enzima α-glucosidasa recombinante humana ha constituido el primer tratamiento...
Language(s): Español
1

Encontrado 8 documentos, página mostrada 1 de 1

Uso de cookies: Este sitio web utiliza cookies propias y de terceros para dar un mejor servicio. Si continúa navegando se considera que acepta su uso. OKMás información